General EvidenceInsights

GLP-1 Weight-Loss Search Interest by Gender

Results as of

Review August 2025 vs. August 2026: Women search for GLP-1 weight-loss treatments 2.5× more than men — a gap that held firm in both 2025 and 2026

GLP-1 Weight-Loss Search Interest by GenderGrouped bar chart showing weighted GLP-1 weight-loss search-interest rates for men and women in Germany for August 2025 and August 2026. Error bars indicate 95% confidence intervals. Women's rates are approximately 2.5 times higher than men's in both years.Grouped bar chart showing weighted GLP-1 weight-loss search-interest rates for men and women in Germany for August 2025 and August 2026. Error bars indicate 95% confidence intervals. Women's rates are approximately 2.5 times higher than men's in both years.
Grouped bar chart showing weighted GLP-1 weight-loss search-interest rates for men and women in Germany for August 2025 and August 2026. Error bars indicate 95% confidence intervals. Women's rates are approximately 2.5 times higher than men's in both years.
Info
Sample size
n = 15,288
Data date
August 2025 vs. August 2026
Segment
male, female
Platform
Search
Market
Germany

Analysis

Women's GLP-1 search-interest rate runs roughly 2.5 times higher than men's in Germany — a structural gap that persisted unchanged from August 2025 to August 2026, and predates the imminent oral Wegovy launch.

A gender skew mirrored in clinical uptake

The pattern is consistent with real-world prescription data. Research on oral semaglutide uptake in other EU markets found the oral form was more frequently used by younger females — aligning with the demographic profile of tablet-specific searchers in Germany, 68% of whom were female. Ahead of the 1 September 2026 Wegovy pill launch in German pharmacies, this persistent gender gap signals that women will likely be the primary adopters of the new oral format — both because they are the dominant research audience now, and because needle aversion may be more prevalent as a stated barrier. The age-group breakdown behind these aggregate rates is explored in GLP-1 search interest by age group.

This analysis is based on public segment data. For deeper cuts, use our Enterprise interface.

Your question

Ask your own question of this data.

This chart is one cut of the panel. In a demo we answer your question on the same data, live.

Book a demo

Methodology

The search-interest rate for each gender is the share of male and female German adult online searchers active in August 2025 or August 2026 who queried GLP-1 weight-loss terms (Wegovy, Ozempic, Saxenda, Mounjaro, semaglutide, tirzepatide, and related terms). Rates are calibrated to the German adult online population (18+) and weighted to reflect demographic composition. The gender comparison is the robust finding; absolute percentages are panel-internal rates.

These insights are based on the General Evidence Panel. Our data comes exclusively from users who are compensated for their anonymity. Become part of the panel & earn from your data